Skip to main content
Equibles

NVO · Novo Nordisk A S · Earnings Call Transcripts & Audio

Track NVO — free

Use NVO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NVO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$37.56 -0.36 (-0.94%)
Rebalance outlook locked
Market Cap
$171.37B
Shares
4.42B
Volume · Oct 1 3.23M Avg daily vol (3M) 12.35M

Novo Nordisk A S Earnings Call Transcripts

Quarterly earnings calls for Novo Nordisk A S (NVO), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Earnings call
FY26 · Q2
2026-08-05
Novo Nordisk A S (NVO) Q2 2026 Earnings Call Transcript
Positive tone Wegovy pill (WagoviPill/VigoviPill) launch and uptake U.S. pricing pressure and channel mix International operations and Wegovy pill ex-U.S. rollout
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-06
Novo Nordisk A S (NVO) Q1 2026 Earnings Call Transcript
Positive tone 2026 financial guidance and operating profit Cost transformation, headcount and SG&A discipline Intellectual property defense and loss of exclusivity
Results not yet reported
Audio Transcript Slides 8-K10-Q
Annual General Meeting
Investor event
2026-03-26
Novo Nordisk A S (NVO) March 2026 Annual General Meeting
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2025-12-31
Novo Nordisk A S (NVO) Q4 2025 Earnings Call Transcript
Positive tone Wegovy pill launch Obesity care growth Pipeline readouts and approvals
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-09-30
Novo Nordisk A S (NVO) Q3 2025 Earnings Call Transcript
Balanced tone Strategic focus on diabetes and obesity GLP-1 franchise performance (Ozempic, Wegovy, Rybelsus) Business development and M&A (Akero, Metsera)
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Novo Nordisk A S (NVO) Q2 2025 Earnings Call Transcript
Cautious tone Obesity care / Wegovy Pipeline and R&D GLP-1 diabetes / Ozempic
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Novo Nordisk A S (NVO) Q1 2025 Earnings Call Transcript
Positive tone GLP-1 volume leadership and patient growth Wegovy U.S. obesity growth Compounding impact and guidance cut
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-09-30
Novo Nordisk A S (NVO) Q3 2024 Earnings Call Transcript
Confident tone GLP-1 scaling and patient reach Pipeline and R&D readouts Obesity care growth
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Novo Nordisk A S (NVO) Q2 2024 Earnings Call Transcript
Confident tone GLP-1 franchise (Ozempic, Wegovy, Rybelsus) Obesity Care and Wegovy supply Sustainability and patients reached
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Novo Nordisk A S (NVO) Q1 2024 Earnings Call Transcript
Confident tone Obesity supply expansion (Wegovy) GLP-1 sales momentum R&D pipeline and readouts
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Novo Nordisk A S (NVO) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Novo Nordisk A S (NVO) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Novo Nordisk A S (NVO) Q2 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Novo Nordisk A S (NVO) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Novo Nordisk A S (NVO) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Novo Nordisk A S (NVO) Q3 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Novo Nordisk A S (NVO) Q2 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Novo Nordisk A S (NVO) Q1 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Novo Nordisk A S (NVO) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Novo Nordisk A S (NVO) Q3 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Novo Nordisk A S (NVO) Q2 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Novo Nordisk A S (NVO) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Novo Nordisk A S (NVO) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Novo Nordisk A S (NVO) Q3 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Novo Nordisk A S (NVO) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Novo Nordisk A S (NVO) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–26 of 26 earnings calls
Key facts CIK 353278 CUSIP 670100205 13F (30d) 31 filings 18 filers Visit website Investor relations